HIV-1, Human Immunodeficiency Virus 1, Human Immunodeficiency Virus Type 1, Immunodeficiency Virus Type 1, Human
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants.
Interventions
DRUGMK-8510
Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Has HIV-1 infection, and is in good health based on medical history, physical examination, vital signs (VS) measurements, and laboratory safety tests. * Has documented HIV-1 positive, as determined by a positive enzyme-linked immunosorbent assay (ELISA) or real-time quantitative polymerase chain reaction (QT-PCR) with confirmation (eg, Western Blot). * Is anti-retroviral therapy (ART)-naïve, which is defined as: 1. Having never received any anti-retroviral agent; or 2. ART-experienced but has not received any ART for HIV-1 infection within 60 days; or 3. Has received pre-exposure prophylaxis (PrEP) treatment prior to diagnosis of HIV-infection but has not received any PrEP within 30 days. * Is willing to receive no other ART prior to Day 11 post-dose of the study. * Has a body mass index (BMI) ≤35 kg/m2.
Exclusion criteria
* Has acute (primary) HIV-1 infection. * Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. * Has remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma). * Is mentally or legally incapacitated or has significant emotional problems. * Has history of cancer (malignancy). * Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e, systemic allergic reaction) to prescription or nonprescription drugs or food. * Has positive hepatitis B surface antigen (HBsAg). * Has a history of chronic hepatitis C unless there has been documented cure and/or participant with a positive serologic test for hepatitis C virus (HCV) has a negative HCV viral load (VL). * Had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit. * Has participated in another investigational study within 4 weeks. * Has a clinically significant abnormality on the electrocardiogram (ECG) performed at the pre-study visit. * Has been committed to an institution by way of official or judicial order. * Is under the age of legal consent or not capable of giving consent. * Does not agree to follow the smoking restrictions as defined by the clinical research unit (CRU). * Consumes greater than 3 servings of alcoholic beverages (1 serving is approximately equivalent to: beer \[354 mL/12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\]) per day. * Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day. * Is a regular user of any illicit drugs (not including cannabis) or has an history of drug (including alcohol) abuse within approximately 12 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) | Baseline and 168 hours post-dose | The plasma HIV-RNA will be measured based on a longitudinal data analysis model containing fixed effects for dose level, and dose level by time interaction, and a random effect of MK-8510 (prodrug). The change from baseline for each dose level at 168-hours post baseline will be estimated from this model. |
| Percentage of Participants Who Experience an Adverse Event (AE) | Up to 36 days | An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
| Percentage of Participants Who Discontinued from Study Due to an Adverse Event (AE) | Up to 36 days | The percentage of participants who discontinue study due to an AE will be presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Concentration (Cmax) of MK-8558 | At protocol specific time points up to 504 hours post-dose | Cmax of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Time to Maximum Plasma Concentration (Tmax) of MK-8558 | At protocol specific time points up to 504 hours post-dose | Tmax of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Half Life (t1/2) of MK-8558 | At protocol specific time points up to 504 hours post-dose | t1/2 of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Area Under the Concentration-Time Curve of MK-8558 From Time 0 to 168 Hours (AUC0-168 hr) | At protocol specific timepoints up to 168 hours post-dose | The AUC0-168 of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168 hours post-dose. |
| Apparent Volume of Distribution in the Terminal State After Extravascular Administration (Vz/F) of MK-8558 | At protocol specific time points up to 504 hours post-dose | Vz/F of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Terminal t1/2 of MK-8558 | At protocol specific time points up to 504 hours post-dose | Terminal t1/2 of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Apparent Plasma Clearance of Drug After Extravascular Administration (CL/F) of MK-8558 | At protocol specific time points up to 504 hours post-dose | CL/F of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Area Under the Concentration-Time Curve of MK-8558 From Time 0 to last (AUC0-last) | At protocol specific time points up to 504 hours post-dose | AUC0-last of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose. |
| Concentration at 168 Hours Post-dose (C168) of MK-8558 | 168 hours post-dose | C168hr of MK-8558 (active drug) after administration of MK-8510 (prodrug) in plasma will be calculated. |
Outcome results
None listed